Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 882 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Headache Disorder Clear all

Conditions: Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions: 40 minute session, 20 minute session, home practice e-health, home practice handout, phone call; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Migraine
Interventions: Eletriptan; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 16
States / cities: Irvine, California • Newport Beach, California • San Francisco, California + 13 more

Conditions: Migraine
Interventions: Lidocaine (drug), Lidocaine Procedure; Drug · Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Migraine Disorders
Interventions: Occipital nerve stimulator; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 10
States / cities: Valencia, California • Chicago, Illinois • Shreveport, Louisiana + 5 more

Conditions: Migraine, Chronic Pain
Interventions: MBSR; Behavioral
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Migraine
Interventions: Fremanezumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 32
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more

Conditions: Workplace Migraine Treatment
Interventions: Triptan, Treximet 85Mg-500Mg Tablet; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine With Aura, Patent Foramen Ovale
Interventions: Not listed
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Migraine Disorders
Interventions: Lasmiditan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: San Diego, California • Hialeah, Florida • Tampa, Florida

Conditions: Migraine, Headache
Interventions: Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Migraine With or Without Aura
Interventions: Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Headache Disorders, Secondary
Interventions: Thoracic manipulation (Manipulation Group), Thoracic Manipulation (Control wait-list); Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Migraine Headache
Interventions: Inhaled Placebo, Inhaled Loxapine 1.25 mg, Inhaled Loxapine 2.5 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Springfield, Missouri • Mount Vernon, New York • East Providence, Rhode Island

Conditions: Cervicogenic Headache, Neck Pain, Posterior
Interventions: Osteopathic Manipulative Therapy and Exercise Therapy; Combination Product
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more

Conditions: Headache Disorder, Sleep Disorder, Obstructive Sleep Apnea
Interventions: Continuous positive airway pressure (CPAP); Device
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cluster Headache
Interventions: Vitamin D, multivitamin, Placebo; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine Headache
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Episodic Cluster Headache
Interventions: Civamide (Zucapsaicin); Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 23 more

Conditions: Migraine
Interventions: Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Migraine, Migraine Disorders
Interventions: Migraine Manager; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 11 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Migraine
Interventions: Precision; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 15
States / cities: Denver, Colorado • Stamford, Connecticut • Augusta, Georgia + 11 more

Conditions: Cluster Headache - Episodic and Chronic
Interventions: SOM230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Culver City, California • Philadelphia, Pennsylvania

Search by objective public record fields.

Mind Body Balance for Pediatric Migraine

Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE

Mindfulness and Migraine Research Study

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

A Study of a Melatonin Receptor Agonist to Prevent Migraine

Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)

A Study of Lasmiditan in Participants With Migraine

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

An Acute Migraine Factorial Study

Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial

Staccato Loxapine in Migraine (Out Patient)

Treating Chronic Cervicogenic Head and Neck Pain

Safety and Efficacy in Adult Subjects With Acute Migraines

Analysis of the Prevalence and Characteristics of Concomitant Sleep and Headache Disorders, and the Efficacy of CPAP Treatment for Headache Among Those Patients Diagnosed With Obstructive Sleep Apnea

High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache

Repeat Dosing of Psilocybin in Migraine Headache

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

Migraine Manager (R01)

Treatment for Migraines With an Implantable Device

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache